Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death

被引:457
作者
El-Assaad, W
Buteau, J
Peyot, ML
Nolan, C
Roduit, R
Hardy, S
Joly, E
Dbaibo, G
Rosenberg, L
Prentki, M
机构
[1] Univ Montreal, Dept Biochem & Nutr, Montreal, PQ H2L 4M1, Canada
[2] McGill Univ, Dept Surg, Montreal, PQ H2L 4M1, Canada
[3] Amer Univ Beirut, Dept Pediat, Beirut, Lebanon
关键词
D O I
10.1210/en.2003-0410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have proposed the "glucolipotoxicity" hypothesis in which elevated free fatty acids (FFAs) together with hyperglycemia are synergistic in causing islet beta-cell damage because high glucose inhibits fat oxidation and consequently lipid detoxification. The effects of 1-2 d culture of both rat INS 832/13 cells and human islet beta-cells were investigated in medium containing glucose ( 5, 11, 20 mM) in the presence or absence of various FFAs. A marked synergistic effect of elevated concentrations of glucose and saturated FFA (palmitate and stearate) on inducing beta-cell death by apoptosis was found in both INS 832/13 and human islet beta-cells. In comparison, linoleate (polyunsaturated) synergized only modestly with high glucose, whereas oleate (monounsaturated) was not toxic. Treating cells with the acyl-coenzyme A synthase inhibitor triacsin C, or the AMP kinase activators metformin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside that redirect lipid partitioning to oxidation, curtailed glucolipotoxicity. In contrast, the fat oxidation inhibitor etomoxir, like glucose, markedly enhanced palmitate-induced cell death. The data indicate that FFAs must be metabolized to long chain fatty acyl-CoA to exert toxicity, the effect of which can be reduced by activating fatty acid oxidation. The results support the glucolipotoxicity hypothesis of beta-cell failure proposing that elevated FFAs are particularly toxic in the context of hyperglycemia.
引用
收藏
页码:4154 / 4163
页数:10
相关论文
共 71 条
  • [1] ESTABLISHMENT OF 2-MERCAPTOETHANOL-DEPENDENT DIFFERENTIATED INSULIN-SECRETING CELL-LINES
    ASFARI, M
    JANJIC, D
    MEDA, P
    LI, GD
    HALBAN, PA
    WOLLHEIM, CB
    [J]. ENDOCRINOLOGY, 1992, 130 (01) : 167 - 178
  • [2] Free fatty acids and pathogenesis of type 2 diabetes mellitus
    Bergman, RN
    Ader, M
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (09) : 351 - 356
  • [3] Chronic exposure to free fatty acid reduces pancreatic β cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation
    Bollheimer, LC
    Skelly, RH
    Chester, MW
    McGarry, JD
    Rhodes, CJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (05) : 1094 - 1101
  • [4] Pancreatic B-cell defects in gestational diabetes: Implications for the pathogenesis and prevention of type 2 diabetes
    Buchanan, TA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) : 989 - 993
  • [5] Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation
    Buteau, J
    Foisy, S
    Rhodes, CJ
    Carpenter, L
    Biden, TJ
    Prentki, M
    [J]. DIABETES, 2001, 50 (10) : 2237 - 2243
  • [6] β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes
    Butler, AE
    Janson, J
    Bonner-Weir, S
    Ritzel, R
    Rizza, RA
    Butler, PC
    [J]. DIABETES, 2003, 52 (01) : 102 - 110
  • [7] The phosphoinositide 3-kinase pathway
    Cantley, LC
    [J]. SCIENCE, 2002, 296 (5573) : 1655 - 1657
  • [8] Abdominal fat and insulin resistance in normal and overweight women - Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM
    Carey, DG
    Jenkins, AB
    Campbell, LV
    Freund, J
    Chisholm, DJ
    [J]. DIABETES, 1996, 45 (05) : 633 - 638
  • [9] CLARK A, 1988, DIABETES RES CLIN EX, V9, P151
  • [10] Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation
    Cnop, M
    Hannaert, JC
    Hoorens, A
    Eizirik, DL
    Pipeleers, DG
    [J]. DIABETES, 2001, 50 (08) : 1771 - 1777